Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin

Surgical Endoscopy

Volumn 27, Issue 6, 2013, Pages 2094-2101

  Jakobsen, Gunn Signe ^a   Skottheim, Ine Blankenberg ^b   Sandbu, Rune ^a   Christensen, Hege ^b   Røislien, Jo ^a,b   Åsberg, Anders ^b   Hjelmesæth, Jøran ^a  

^a VESTFOLD HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Atorvastatin; Biliopancreatic diversion with duodenal switch; Gastric bypass; Systemic exposure

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH BYPASS; SYSTEMIC THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84885039260     PISSN: 09302794     EISSN: 14322218     Source Type: Journal    
DOI: 10.1007/s00464-012-2716-3     Document Type: Article

References (33)

1. Aasheim ET, Bjorkman S, Sovik TT, Engstrom M, Hanvold SE, Mala T, Olbers T, Bohmer T (2009) Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr 90:15-22
2. Buchwald H, Oien D (2009) Metabolic/bariatric surgery worldwide 2008. Obes Surg 19:1605-1611
3. De Smet J, Colin P, De Paepe P, Ruige J, Batens H, Van Nieuwenhove Y, Vogelaers D, Blot S, Van Bocxlaer J, Van Bortel LM, Boussery K (2012) Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 67:226-229
4. Drozdowski LA, Clandinin MT, Thomson AB (2009) Morphological, kinetic, membrane biochemical, and genetic aspects of intestinal enteroplasticity. World J Gastroenterol 15:774-787
5. Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171
6. Dudrick SJ, Daly JM, Castro G, Akhtar M (1997) Gastrointestinal adaptation following small bowel bypass for obesity. Ann Surg 185:642-648
7. Edwards A, Ensom MH (2012) Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 46:130-136
8. Fenyo G, Backman L, Hallberg D (1976) Morphological changes of the small intestine following jejuno-ileal shunt in obese subjects. Acta Chir Scand 142:154-159
9. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI (1984) Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61:27-35
10. Hall KD (2010) Predicting metabolic adaptation, body weight change, and energy intake in humans. Am J Physiol Endocrinol Metab 298:E449-E466
11. Hamad GG, Helsel JC, Perel JM, Kozak GM, McShea MC, Hughes C, Confer AL, Sit DK, McCloskey CA, Wisner KL (2012) The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 169:256-263
12. Hermann M, Christensen H, Reubsaet JL (2005) Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 382:1242-1249
13. Hofso D, Aasheim ET, Sovik TT, Jakobsen GS, Johnson LK, Sandbu R, Aas AT, Kristinsson J, Hjelmesaeth J (2011) Follow-up after bariatric surgery. Tidsskr Nor Laegeforen 131:1887-1892
14. Karlsson J, Taft C, Ryden A, Sjostrom L, Sullivan M (2007) Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes London 31:1248-1261
15. le Roux CW, Borg C, Wallis K, Vincent RP, Bueter M, Goodlad R, Ghatei MA, Patel A, Bloom SR, Aylwin SJ (2010) Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg 252:50-56
16. Michalakis K, le Roux C (2012) Gut hormones and leptin: impact on energy control and changes after bariatric surgery: what the future holds. Obes Surg 22:1648-1657
17. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216
18. Padwal R, Brocks D, Sharma AM (2010) A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 11:41-50
19. Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, Brocks DR (2011) Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 34:1295-1300
20. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562
21. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24
22. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886
23. R Development Core Team (2008) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 900051-07-0. http://www.R-project.org
24. Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L (2012) Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis 8:62-66
25. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA (2008) Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transpl 22:281-291
26. Rubio I, Galrão A, Santo M, Zanini A, Medeiros-Neto G (2012) Levothyroxine absorption in morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB) surgery. Obes Surg 22:253-258
27. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693
28. Skottheim IB, Jakobsen GS, Stormark K, Christensen H, Hjelmesaeth J, Jenssen T, Asberg A, Sandbu R (2010) Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther 87:699-705
29. Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, Reubsaet JL, Sandbu R, Asberg A (2009) Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther 86:311-318
30. Spak E, Björklund P, Helander HF, Vieth M, Olbers T, Casselbrant A, Lönroth H, Fändriks L (2010) Changes in the mucosa of the Roux limb after gastric bypass surgery. Histopathology 57:680-688
31. Stein TA, Wise L (1978) Functional adaptation of the intestinal mucosal enzymes after jejunoileal bypass for morbid obesity. Am J Clin Nutr 31:1143-1148
32. Stock-Damge C, Aprahamian M, Raul F, Marescaux J, Scopinaro N (1986) Small-intestinal and colonic changes after biliopancreatic bypass for morbid obesity. Scand J Gastroenterol 21:1115-1123
33. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y (2002) Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 277:32453-32458